11th Annual Forum for Qualified Persons in Pharmacovigilance

This is the only forum designed for QPPVs by QPPVs, now in its 11th year and ever growing. This year’s objectives build on past successes and have been shaped by valuable feedback provided by participants.

戻る Agenda

Session 3: Hot Topics – A Regulators’ Perspective

Session Chair(s)

Doris Irene Stenver, MD, MPA

Independent Pharmacovigilance Adviser, Unique Advice, Denmark

The activities in the Pharmacovigilance Risk Assessment Committee (PRAC) covers a wide range of procedures, and the level of experience has reached a high level of matureness more than 5 years after the 2012 EU pharmacovigilance legislation came into force. For the QPPV it is important to keep abreast with the PRAC activities, and the current session will provide valuable insight into the functioning of the PRAC. Which are the current hot topics the committee is dealing with? Who are the most important stakeholders and how does the PRAC cooperate with them? Answers to these and many more questions will be provided in this session.

Speaker(s)

Doris Irene Stenver, MD, MPA

Independent Pharmacovigilance Adviser, Unique Advice, Denmark

PRAC updates

Sabine Straus, MD, PHD, MSC

Former PRAC Chair, Medicines Evaluation Board (MEB), Netherlands

Feedback on PRAC´s First Public Hearing and Highlights on Signal Management

Emil Andrei Cochino, MD, MHS

Scientific Senior Specialist (Risk Management), European Medicines Agency, Netherlands

The RMP in the life cycle of the product – originator/generic/biosimilar

Nuria Semis-Costa, MSC

Scientific Specialist (Risk Management), European Medicines Agency, Netherlands

The RMP in the life cycle of the product – originator/generic/biosimilar

11th Annual Forum for Qualified Persons in Pharmacovigilance

Session 3: Hot Topics – A Regulators’ Perspective

Session Chair(s)

Doris Irene Stenver, MD, MPA

Speaker(s)

Doris Irene Stenver, MD, MPA

Sabine Straus, MD, PHD, MSC

Emil Andrei Cochino, MD, MHS

Nuria Semis-Costa, MSC

最新情報や機会を逃さないで